China's biopharmaceutical output exceeds 2 trillion renminbi for 2013
The production value of China's bio-medicine industry amounted to 2.1 trillion renminbi ($338.8 billion) in 2013, up about 18% year on year, the country's top economic planner announced on Monday, reports the state news agency Xinhua.
Zhang Xiaoqiang, vice director of the National Development and Reform Commission, said the country was accelerating its research and development of new medicines, new types of plants and animals and new material products.
"In 2014 and 2015, China should strive to promote biological development including bio-pharmaceutical, bio-agriculture and bio-energy," said Mr Zhang at a news briefing ahead of a biological industry national conference.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze